Zevra Therapeutics Inc (ZVRA)
9.52
+0.39
(+4.27%)
USD |
NASDAQ |
Nov 22, 13:24
Zevra Therapeutics Total Liabilities (Quarterly): 121.78M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 121.78M |
| June 30, 2024 | 111.93M |
| March 31, 2024 | 102.46M |
| December 31, 2023 | 110.46M |
| September 30, 2023 | 71.51M |
| June 30, 2023 | 37.02M |
| March 31, 2023 | 35.19M |
| December 31, 2022 | 40.22M |
| September 30, 2022 | 25.76M |
| June 30, 2022 | 25.02M |
| March 31, 2022 | 4.207M |
| December 31, 2021 | 5.823M |
| September 30, 2021 | 5.449M |
| June 30, 2021 | 8.134M |
| March 31, 2021 | 6.184M |
| December 31, 2020 | 77.62M |
| September 30, 2020 | 73.53M |
| June 30, 2020 | 75.19M |
| March 31, 2020 | 77.56M |
| December 31, 2019 | 84.96M |
| Date | Value |
|---|---|
| September 30, 2019 | 83.51M |
| June 30, 2019 | 94.56M |
| March 31, 2019 | 94.70M |
| December 31, 2018 | 93.31M |
| September 30, 2018 | 114.08M |
| June 30, 2018 | 117.54M |
| March 31, 2018 | 122.33M |
| December 31, 2017 | 109.97M |
| September 30, 2017 | 107.41M |
| June 30, 2017 | 108.32M |
| March 31, 2017 | 109.57M |
| December 31, 2016 | 103.58M |
| September 30, 2016 | 104.35M |
| June 30, 2016 | 104.30M |
| March 31, 2016 | 123.42M |
| December 31, 2015 | 64.71M |
| September 30, 2015 | 67.16M |
| June 30, 2015 | 63.08M |
| March 31, 2015 | 68.47M |
| December 31, 2014 | 62.22M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
4.207M
Minimum
Mar 2022
121.78M
Maximum
Sep 2024
55.00M
Average
55.87M
Median
Total Liabilities (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | 2.419B |
| Vanda Pharmaceuticals Inc | 103.89M |
| BioCardia Inc | 3.514M |
| Xeris Biopharma Holdings Inc | 349.43M |
| Instil Bio Inc | 96.23M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 191.55M |
| Shareholders Equity (Quarterly) | 69.77M |
| Debt to Equity Ratio | 0.8443 |
| Current Ratio | 2.884 |
| Net Debt Paydown Yield | -2.50% |